
Lucian Chirieac M.D.
Assistant Professor, Department of Pathology, Harvard Medical School
Associate Pathologist, Department of Pathology, Brigham and Women's Hospital
Contact Info
Lucian Chirieac
Brigham and Women's Hospital
75 Francis Street
Boston, MA, 02115
Mailstop:
Phone: 6177328126
Fax: 6172645118
lchirieac@partners.org
Phone: 6177324742
Fax:
lkwan@partners.org
Brigham and Women's Hospital
75 Francis Street
Boston, MA, 02115
Mailstop:
Phone: 6177328126
Fax: 6172645118
lchirieac@partners.org
Assistant
Laura KwanPhone: 6177324742
Fax:
lkwan@partners.org
DF/HCC Program Affiliation
Member, Lung Cancer ProgramResearch Abstract
My aim is to provide laboratory expertise that is available for collaborative projects with the Departments of Pulmonary Medical Oncology and Surgery at Dana Farber. This will include obtaining normal and neoplastic tissue (frozen-tissue bank, paraffin blocks), immunohistochemistry, in situ hybridization, laser capture microdissection, and DNA retrieval and analysis. My efforts are dedicated to the identification and investigation of the molecular genetics and genomics of pulmonary neoplasia with an emphasis on translational applications to the management of patients with pulmonary and pleural-based cancer. Based on this work we will be able to refine our ability to predict the tumor response to therapy and to prognosticate with a higher probability a patient’s disease-free and overall survival.Publications
- Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007 Aug 16; 448(7155):807-10
PMID: 17676035 - Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol 2007 Oct; 20(10):1028-35
PMID: 17673923 - Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jänne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007 Jul; 12(1):81-93
PMID: 17613438 - Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007 Jul; 9(3):320-6
PMID: 17591931 - Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE,. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006 Jul; 4(6):548-82
PMID: 16813724 - Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006 Jun; 9(6):485-95
PMID: 16730237 - Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006 Apr 1; 24(10):1561-7
PMID: 16575008 - Jackman DM, Chirieac LR, Jänne PA. Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. Semin Respir Crit Care Med 2005 Jun; 26(3):342-52
PMID: 16052436 - Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, Hamilton SR, Wu TT. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res 2005 Mar 15; 11(6):2229-36
PMID: 15788671 - Chirieac LR, Shen L, Catalano PJ, Issa JP, Hamilton SR. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am J Surg Pathol 2005 Apr; 29(4):429-36
PMID: 15767794 - Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005 Apr 1; 103(7):1347-55
PMID: 15719440



